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Abstract.
Background: Understanding how dysregulation in lipid metabolism relates to the severity of Alzheimer‘s disease (AD)
pathology might be critical in developing effective treatments.
Objective: To identify lipid species in cerebrospinal fluid (CSF) associated with signature AD pathology and to explore their
relationships with measures reflecting AD-related processes (neurodegeneration, inflammation, deficits in verbal episodic
memory) among subjects at the pre- and early symptomatic stages of dementia.
Methods: A total of 60 subjects that had been referred to an Icelandic memory clinic cohort were classified as having CSF AD
(n = 34) or non-AD (n = 26) pathology profiles. Untargeted CSF lipidomic analysis was performed using ultra-performance
liquid chromatography-tandem mass spectrometry (UPLC-MS) for the detection of mass-to-charge ratio (m/z) features. CSF
proteins reflecting neurodegeneration (neurofilament light [NFL]) and inflammation (chitinase-3-like protein 1 [YKL-40],
S100 calcium-binding protein B [S100B], glial fibrillary acidic protein [GFAP]) were also measured. Rey Auditory Verbal
Learning (RAVLT) and Story tests were used for the assessment of verbal episodic memory.
Results: Eight out of 1008 features were identified as best distinguishing between the CSF profile groups. Of those, only
the annotation of the m/z feature assigned to lipid species C18 ceramide was confirmed with a high confidence. Multiple
regression analyses, adjusted for age, gender, and education, demonstrated significant associations of CSF core AD markers
(A42: st. = –0.36, p = 0.007; T-tau: st. = 0.41, p = 0.005) and inflammatory marker S100B (st. = 0.51, p = 0.001) with C18
ceramide levels.
Conclusion: Higher levels of C18 ceramide associated with increased AD pathology and inflammation, suggesting its
potential value as a therapeutic target.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative
disease that leads to progressive cognitive impair-
ment and dementia. The pathology of AD, which
starts decades before the appearance of clinical symp-
toms [1], is characterized by extracellular amyloid
plaques containing amyloid- (A) and intracel-
lular neurofibrillary tangles (NFTs) comprised of
phosphorylated tau (P-tau) [2, 3]. The most widely
accepted hypothesis regarding AD pathogenesis pro-
poses that the deposition of A leads to formation
of NFTs, neuronal dysfunction, and dementia [4].
Although abundant evidence places A and tau
pathology at the center of AD pathogenesis, the
mechanisms linking the two together and to even-
tual neuronal dysfunction and death are still unclear
[4, 5]. As A and tau pathology levels are relatively
constant in the symptomatic stages of the disease,
they are not considered suitable as progression mark-
ers [6–9]. Biomarkers reflecting other aspects of AD
pathology are therefore needed. Genome-wide asso-
ciation studies have identified about 30 risk genes
with a high proportion related to lipid metabolism,
immune response, or both [10, 11]. These findings
suggest that dysregulation of lipids and inflamma-
tory proteins play an essential part in the pathogenesis
of AD.
Lipids play various roles in the human body, both
as structural components of cell membranes and in
diverse biochemical processes, including membrane
trafficking and cell signaling [12]. A dozen of major
lipid classes are found within eukaryotic organisms,
each comprising hundreds of individual molecular
species [13]. Major classes, including glycerophos-
pholipids, sphingolipids, fatty acids, and cholesterol
[14], are abundantly expressed in the brain. These
lipids are utilized in different compartments of glial
cells and neurons [15]. In recent years, the role of lipid
metabolism defects in AD pathogenesis has gained
increased attention. Several molecular mechanisms
have been identified, which connect membrane lipids
to the generation and aggregation of A. Pathologi-
cal forms of A proteins are formed by proteolytic
cleavage of the transmembrane protein APP by -
and -secretases [16]. Lipid membrane structure and
organization can affect the activity of these trans-
membrane enzymes, and thus APP processing and
A production [17]. Furthermore, secretases, APP,
and its derivatives also appear to affect the activity of
lipid metabolic enzymes and subcellular trafficking,
thereby changing the membrane lipid composition.
Lipids might, therefore, play a role in the initiation
and progression of AD pathogenesis [16].
Studies have established neuroinflammation as a
contributing factor in the pathogenesis and progres-
sion of AD and other neurodegenerative diseases
[18, 19]. A plaques induce an immune response
by activation of microglia and astrocytes [20–22],
which in turn is thought to play a role in the forma-
tion of NFTs, contributing to neuronal dysfunction
and loss [23]. The glial proteins chitinase-3-like-1
protein (YKL-40), calcium-binding protein S100B,
and glial fibrillary acidic protein (GFAP) have been
associated with AD pathology [24]. All proteins are
expressed primarily (YKL-40 and S100B) [25, 26], or
exclusively (GFAP) [27] in astrocytes within the cen-
tral nervous system (CNS). YKL-40, a chitin-binding
glycoprotein [28], has been reported to be a promis-
ing candidate biomarker of glial activation in AD.
Previous studies have detected positive relationships
between YKL-40 and the neurodegeneration mark-
ers tau [29–32] and neurofilament light (NFL) [33] in
cerebrospinal fluid (CSF), demonstrating an associa-
tion between glial activation and neurodegeneration
[34]. NFL is mainly located in myelinated axons, with
recent studies indicating a potential for this protein as
both a diagnostic and a progression marker in AD and
other neurodegenerative diseases [35, 36]. S100B,
a calcium-binding protein, exerts both intracellular
and extracellular functions and has been found to be
upregulated in AD tissues [37, 38]. GFAP is an inter-
mediate filament protein and a marker for astrocyte
activation, which has both been associated with amy-
loid plaque load and the number of NFTs [39–41].
In recent years, a paradigm shift has occurred from
clinical to biological definition of AD based on in vivo
biomarkers measured in CSF or with positron emis-
sion tomography (PET) imaging [1]. The most recent
research criteria base the diagnosis of AD partly
[42] or primarily [1] on signature profiles defined by
CSF/PET A, CSF total tau (T-tau), and CSF P-tau
levels. The International Working Group (IWG) [42],
for example, defines typical AD as a combination
of biomarker evidence (decreased CSF/PET A42
together with increased CSF T-tau or P-tau) and a
specific phenotype (presence of a significant episodic
memory impairment). Although the diagnostic accu-
racies of these core biomarkers are satisfactory [43],
there is still a need to examine others. Understand-
ing how biomarkers reflecting other processes could
influence AD pathogenesis and severity is critical for
the improvement of diagnosis and development of
effective pharmacologic treatments. The first aim of
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Fig. 1. Flow diagram of sample selection and lipid profiling techniques applied to the analysis of CSF samples.
this study was to identify CSF lipid species associated
with CSF profile reflecting signature AD pathology
in a cohort of subjects at the pre- and early symp-
tomatic stages of dementia. The second aim was
to explore the relationships between candidate lipid
species and measures reflecting other AD-associated
processes, including neuronal generation, inflamma-
tion and impairment in verbal episodic memory.
MATERIALS AND METHODS
Subjects
Subjects from The Icelandic MCI study cohort
(n = 218), who had undergone lumbar puncture, were
selected for this cross-sectional study (n = 64). The
cohort was comprised of individuals who had been
referred to Landspitali University Hospital (LUH)
Memory Clinic over a four-year period (Fig. 1). The
inclusion criteria for joining the cohort study were:
1) a score between 24–30 on the Mini-Mental State
Examination (MMSE) [44] and 2) a score of 4.0 or
less on the Informant Questionnaire on Cognitive
Decline in the Elderly (IQCODE) [45]. The exclusion
criteria were the following: 1) cognitive impairment
caused by a pre-existing condition, 2) difficulties
participating due to health or social issues, and 3)
residency outside the Reykjavı́k Capital Area. Each
subject underwent various measurements at base-
line, which included a medical assessment and a
detailed neuropsychological assessment as well as
brain magnetic resonance imaging (MRI) for the eval-
uation of medial temporal lobe atrophy (MTA) and
white matter lesions. Lumbar puncture was carried
out for the collection of CSF, but the intervention was
optional required by the National Bioethics Commit-
tee. The final sample included 60 subjects as four
were removed due to excessively high CSF GFAP
value (n = 1) or blood-contamination in CSF sam-
ples (n = 3). Clinical diagnosis of AD was based on
the criteria for probable AD dementia defined by the
National Institute on Aging-Alzheimer’s Association
(NIA-AA) [46], with evidence of AD pathophys-
iological processes (based on MTA score or/and
analysis of core CSF markers). Patients with Lewy
body dementia (LBD) were diagnosed based on the
consensus criteria of McKeith [47]. The diagnosis of
mild cognitive impairment (MCI) required the ful-
fillment of the Winblad criteria [48]. Those without
cognitive impairment were considered to have sub-
jective cognitive impairment (SCI), as they had been
referred to the Memory Clinic due to concerns of cog-
nitive decline. Of the 60 participants in this study, 13
were diagnosed with SCI, 23 with MCI, 20 with AD,
three with LBD, and one with Parkinson’s disease.
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The study has been approved by the National
Research Ethics Committee of Iceland (VSN-14-
028) and all subjects signed an informed consent. The
study was conducted in accordance with the Helsinki
Declaration latest revision of 2013.
CSF collection and analysis
Collection of CSF was done via lumbar puncture
with a 22-gauge spinal needle at the L3/4 or L4/
5 interspace. Samples, uncentrifuged, were frozen
in 2 ml polypropylene tubes and stored at –80◦C.
Levels of all proteins were determined using commer-
cially available sandwich enzyme-linked immuno-
sorbent assays (ELISAs) and performed according
to manufacturer‘s instructions. Levels of T-tau (IBL
International, Hamburg, Germany), P-tau181 (INNO
TEST, Gent, Belgium), and A42 (IBL Interna-
tional, Hamburg, Germany), were measured in the
ISO 15189 accredited medical laboratory MVZ
Labor P.D. Dr. Volkmann und Kollegen GbR (Karls-
ruhe, Germany). Levels of NFL (Uman Diagnos-
tics, Umeå, Sweden), YKL-40 (Quantikine ELISA
Human Chitinase-3–like 1; R&D systems, MN,
USA), S100B (BioVendor GmbH, Heidelberg, Ger-
many), and GFAP (BioVendor GmbH, Heidelberg,
Germany) were measured in a laboratory at the Uni-
versity of Iceland. All assays had mean Intra-assay
CV < 10% and Inter-assay CV < 15%.
Subject grouping based on CSF measures
Each subject was classified based on CSF T-tau
and A42 values, independently of clinical diagnosis.
A cut-off of 0.52 for T-tau/A42 ratio was selected
based on results from a large memory clinic cohort
study [49]. T-tau/A42 ratio > 0.52 was defined as a
signature CSF AD profile. The CSF AD profile group
had a total of 34 subjects (20 with a clinical diagnosis
of AD dementia, 10 with MCI, three with SCI and
one with Lewy body dementia) while the non-AD
profile had a total of 26 subjects (13 with MCI, 10
with SCI, two with LBD, and one with Parkinson’s
disease). The same ratio cut-off point was also used
as a part of the clinical diagnosis of AD, explaining
full concordance with the CSF AD profile.
Neuropsychological tests
A detailed neuropsychological assessment, for
the evaluation of different cognitive domains, was
performed by licensed psychologists under the
supervision of a clinical neuropsychologist. A signifi-
cant impairment in episodic memory is commonly the
earliest clinical symptom of AD [50], and therefore
of specific interest here. Two tests were used for the
evaluation of verbal episodic memory, The Rey Audi-
tory Verbal Learning Test (RAVLT) [51], and a Story
test based on the Logical Memory test of the Wechsler
Memory Scale-Revised [52]. RAVLT consists of 15
nouns presented across five consecutive trials, with
each trial followed by a free-recall test (immediate
recall). A score for RAVLT immediate recall was cal-
culated by summing up the number of words recalled
from trials 1 through 5 (0 to 75 points). After a 30 min
delay, subjects were required to recall the words with-
out being reread the list (delayed recall). A point was
given for each correct word (0 to 15 points). The sec-
ond test was composed of an orally presented story,
which included 25 ideas. Right after the presentation,
the subject was asked to repeat what they remembered
without being given any clues. After a 30 min delay,
there was another recall without the story being reread
to the subject. For both immediate and delayed recall,
a point was given for each idea (0 to 25 points).
Sample preparation and scanning UPLC-MS
analysis
CSF sample extraction was based on the method
used in Bird et al. [53]. Briefly, C12 ceramide and
C17 sphingomyelin (SM d18:1/17:0) were purchased
from Avanti Polar Lipids (Alabaster, AL, USA) and
added to 30 l of CSF as internal standards prior
to lipid extraction. Dried lipid extracts were resus-
pended in 300 L of ACN/IPA/H2O (65:30:5 v/v/v)
and stored at –80◦C prior to analyses. C18 SM
(d18:1/18:0) and C18 ceramide (d18:1/18:0) were
run alongside samples for reference as both SMs
and ceramides have consistently been associated with
AD [54]. Ultra-performance liquid chromatography-
tandem mass spectrometry (UPLC-MS) lipidomic
analysis was carried out as described in Kotronoulas
et al. [55]. The analytical instrumentation used was an
ACQUITY UPLC system (UPLC ACQUITY, Waters
Corporation, Milford, MA) coupled to a traveling-
wave ion mobility (IMS) qTOF mass spectrometer
(Synapt G2 HDMS, Waters Corporation, Manch-
ester, UK). The chromatographic gradient separation
was performed on an ACQUITY CSH C18 column
(2.1 mm × 150 mm, 1.7 m particle size, Waters
Corporation) at 60◦C (Supplementary Figure 1).
Mobile phase A was H2O/2-isopropanol (80:20) and
mobile phase B 2-isopropanol/ACN/H2O (90:9.1),
U.D. Teitsdottir et al. / Markers of Alzheimer’s Disease and Inflammation at the Pre- and Early Stages of Dementia 235
both with 0.05% of formic acid and 5 mM ammonium
formate. Injection volume was 10 L, flow rate was
0.4 mL/min, and the run time was 17 min. The fol-
lowing gradient pattern (solvent B) was used: 0 min,
40%B; 1 min, 40%B; 3 min, 60%B; 10 min, 100%B;
13.5 min, 100%B; 14 min, 40%B; 17 min, 40 %B.
Both positive (+) and negative (-) electrospray ion-
ization (ESI) modes were acquired. The capillary and
cone voltage were 2.5 kV and 30 V, respectively. The
source and desolvation temperature were 120 and
500◦C and the desolvation gas flow was 800 L/h. Dur-
ing High Definition MSE (HDMSE) experiments, the
collision energy in the trap cell was off, and in the
transfer cell, it ranged from 20 to 30 eV for the posi-
tive mode and from 25 to 40 eV for the negative mode.
The resulting MS data were analyzed further within
the MS-Dial program.
Spectral processing
Waters RAW files were converted to ABF format
using the Reifycs Abf Converter tool. All patient
ABF files and pooled samples from either positive
or negative controls were loaded into the MS-Dial
application [56]. MS-Dial was used for sample align-
ment and peak detection. Selected mass-to-charge
ratio (m/z) peaks, hereafter referred to as m/z fea-
tures, were manually curated to minimize the effect
of sample drift. All m/z features were normalized to
the internal standards. M/z feature annotation was
performed with MS-Dial and compared to MS/MS
spectra in the LipidBlast Library [57]. A total of
1013 m/z features were detected based on their peak
mass. M/z features with more than 5% missing val-
ues were excluded from the analysis (n = 5), leaving
1008 features. The remaining missing data (5% or
less) were imputed by the smallest observed value of
that particular feature.
Statistical analysis
All CSF measures (detected m/z features and
proteins) were log2-transformed to fit a Gaussian dis-
tribution. After autoscaling, each CSF measure had an
average and a standard deviation of 0 and 1, respec-
tively. Mann-Whitney U non-parametric tests were
performed to compare levels of different variables
between CSF profile groups. The sample (n = 60)
was divided into the two sets (discovery and valida-
tion) using a bootstrap sampling method [58] for the
selection of m/z features best distinguishing between
CSF AD and non-AD profile groups. A discovery set
was created by drawing a random sample of equal
size from the original sample (n = 60) with replace-
ment. Approximately 63% of the sample (38 subjects)
were selected into the discovery set, and those left
out (22 subjects) made up the validation set. The
levels of each m/z feature were compared between
CSF profile groups in both sets using Mann-Whitney
U tests with a significance level of 0.05. This pro-
cedure was repeated 1000 times for the purpose of
enhancing the robustness of feature selection. The
m/z features most frequently significant in both sets
(> 20%) were selected for more detailed identifica-
tion. The cut-off point of 20% was selected based on
the distribution of m/z features after 1000 bootstrap
replications (Supplementary Figure 2). A cut-off at
20% was considered optimal, as frequencies of sig-
nificant m/z features started to slowly increase below
that point. Pearson’s correlations and linear regres-
sion models (both unadjusted and adjusted for gender,
age, and years of education) were used for estimation
of relationships between continuous measures and
final selection of lipids. All statistical analyses were
performed using R (version 3.6.1, The R Foundation
for Statistical Computing).
RESULTS
Table 1 presents the demographic, pathophysiolog-
ical, and cognitive characteristics of subjects, both
within the whole sample and divided by CSF pro-
file (AD and non-AD). No statistical differences (p >
0.05) were found between CSF profile groups by gen-
der, age, education, CSF protein levels, or MMSE
scores. Subjects with a CSF AD profile performed
worse on tests assessing verbal episodic memory,
both for immediate (RAVLT: p = 0.009; Story: p =
0.003) and delayed (RAVLT: p < 0.001; Story: p =
0.002) recall.
In order to relate changes in lipid species levels
to typical AD pathology and related measures, we
performed a lipidomic analysis of CSF from patients
described in Table 1. The selection of the m/z fea-
tures best distinguishing between CSF profile groups
was done using Mann-Whitney U non-parametric
tests. Of the 1008 features detected, eight signifi-
cantly differed in levels between groups within both
the discovery and validation sets in more than 200 of
the 1000 (20%) bootstrap replicates (Fig. 2) and were
selected for further identification. Eight m/z features
reached significance in 10–20% of the replicates, 23
in 2–10% of the replicates and 969 in less than 2%
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Table 1
Subject demographics, CSF protein levels and cognitive scores by CSF profile
CSF profile All
Non-AD AD
T-tau/ A42 ≤ 0.52 T-tau/ A42 > 0.52 pa
n = 26 n = 34 n = 60
Demographics
Gender (M/F) 16/10 16/18 0.27 32/28
Age, y 68 (46–85) 70 (51–84) 0.19 70 (46–85)
Education, y 14 (9–20) 13 (6–20) 0.82 13 (6–20)
Clinical diagnosis
SCI/MCI/AD/LBD/PD 10/13/0/2/1 3/10/20/1/0 N/Ad 13/23/20/3/1
CSF measuresb
A42 (pg/ml) 770 (374–2332) 470 (140–977) N/Ae 555 (140–2332)
T-tau (pg/ml) 182 (100–722) 429 (132–1086) N/Ae 290 (100–1086)
P-tau (pg/ml) 45 (24–77) 84 (30–144) N/Ae 58 (24–144)
NFL (ng/ml) 2.0 (0.9–6.5) 2.5 (1.2–5.3) 0.052 2.2 (0.9–6.5)
YKL-40 (ng/ml) 165 (83–399) 189 (124–367) 0.35 183 (83–399)
S100B (pg/ml) 215 (132–335) 240 (129–509) 0.06 228 (129–509)
GFAP (ng/ml) 1.1 (0.1–7.1) 1.3 (0.5–21.3) 0.11 1.3 (0.1–21.3)
Global cognition
MMSE, score 28 (24–30) 28 (24–30) 0.87 28 (24–30)
Verbal episodic memory
RAVLT immediate recall, scorec 34.5 (23–66) 27 (13–58) 0.009 30 (13–66)
RAVLT delayed recall, scorec 4.5 (0–15) 1 (0–12) < 0.001 3 (0–15)
Story – immediate recall, score 13.5 (5–17) 8 (1–21) 0.003 10 (1–21)
Story – delayed recall, score 11.5 (1–19) 6 (0–19) 0.002 7 (0–19)
AD, Alzheimer’s disease; CSF, Cerebrospinal fluid; LBD, Lewy body dementia; MCI, mild cognitive impairment;
MMSE, Mini-Mental State Examination; N/A, Not applicable; PD, Parkinson‘s disease; RAVLT, Rey Auditory
Verbal Learning Test; SCI, subjective cognitive impairment. Values are shown as median (range) or as numbers per
group. aMann-Whitney U non-parametric test used for continuous variables and Chi-Square test for the categorical
variable (gender). bRaw values (neither log2-transformed nor autoscaled). cAnalysis based on 59 subjects, one
missing value. dp-values not applicable for clinical diagnosis due to CSF profiles being part of the diagnostic
criteria for AD. ep-values not applicable for A42 and tau due to their values used for defining CSF profiles.
Fig. 2. Frequencies of m/z features significantly distinguishing between CSF profiles (AD and non-AD) in both discovery and validation
sets (p < 0.05) after 1000 bootstrap replications. A total of eight features with frequencies higher than 200 (20%) were selected for more
detailed identification.
of the replicates. The distribution of all m/z features
after 1000 boostrap replications is depicted in Sup-
plementary Figure 2.
Table 2 presents the lipid species annotations that
were automatically assigned to the eight selected
m/z features using the LipidBlast spectral library. It
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Table 2
LipidBlast annotations of the eight selected m/z features. Levels for each feature compared between CSF AD and non-AD profile groups
Feature/peak Average RT Ionization Annotated lipid Proposed structure CSF profilea pb
(m/z) (min) mode species
Non-AD AD
607.472 7.74 (-) FAHFA 40:7 FAHFA (18:5/22:2) –0.50 0.25 < 0.001
607.375 6.00 (-) MGDG 20:0 MGDG (10:0/10:0) –0.54 –0.05 < 0.001
579.441 7.24 (-) FAHFA 38:7 FAHFA (18:4/20:3) –0.42 0.27 < 0.001
663.441 6.15 (-) MGDG 24:0 MGDG (10:0/14:0) –0.28 0.38 < 0.001
564.537 7.50 (-) Cer 36:1 C18 Cer (d18:1/18:0) –0.48 0.31 0.002
783.496 6.65 (-) PMeOH 42:9 PMeOH (20:3/22:6) –0.36 0.29 0.003
664.386 6.21 (-) PE 32:6e PE (16:23/16:4) –0.10 0.36 0.003
635.503 8.07 (-) FAHFA 42:7 FAHFA (20:3/22:4) –0.56 –0.11 0.005
m/z, mass-to-charge ratio; RT, retention time; Cer, ceramide; FAHFA, fatty acid ester of hydroxyl fatty acid; MGDG, monogalactosyldiacyl-
glycerol; PE, phosphatidylethanolamines; PMeOH, phosphatidyl methanol. aBased on normalized peak area arbitrary units (A.U.), log2-
transformed and autoscaled before analysis. bMann-Whitney U non-parametric test used.
also includes comparisons in levels of each feature
between CSF profiles. Annotations of compounds
searching the library are based on similarity match-
ing of elements, including m/z peaks and retention
time (RT). The lipid species selected belonged to
four different lipid categories; glycerophospholipids
(PE 16:23/16:4, PMeOH 20:3/22:6), sphingolipids
(ceramide d18:1/18:0), branched fatty acid esters of
hydroxy fatty acids (FAHFA 18:5/22:2, 18:4/20:3
and 20:3/22:4), and monogalactosyldiacylglycerol
(MGDG 10:0/10:0). Of the eight lipid species anno-
tated via LipidBlast library search, a reference
standard was only run for C18 ceramide (d18:1/18:0).
A comparison of the MS/MS fragmentation spectra of
the C18 ceramide standard confirmed the annotation
of C18 ceramide in the CSF samples (Supplemen-
tary Figure 3). The other seven annotated lipid species
remain unconfirmed, as a comparison of each MS/MS
fragmentation spectra to the LipidBlast reference
spectra did not clearly confirm the correct chemical
structure. All measured m/z features are listed in Sup-
plementary Table 1A (positive ionization mode) and
1B (negative ionization mode).
As the structure for C18 ceramide was confir-
med with high confidence, it was selected for fur-
ther analysis. Figure 3 presents the levels of CSF
C18 ceramide by different CSF profiles. As can be
observed, levels of C18 ceramide were elevated in
the CSF AD profile group compared to the non-AD
group (p = 0.002).
Linear regression (unadjusted and adjusted for
gender, age, and education) was performed to esti-
mate the relationships of established AD (A42,
T-tau, P-tau), inflammatory (YKL-40, S100B, GFAP)
and neuronal degeneration (NFL) markers with
CSF C18 ceramide (Table 3). Levels of A42
Fig. 3. Comparison in levels of CSF C18 ceramide by CSF profile
(non-AD and AD). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 significance
according to Mann-Whitney U non-parametric test. Based on nor-
malized peak area arbitrary units (A.U.), log2-transformed and
autoscaled before analysis. The lower and upper horizontal lines
of the boxplot correspond to the 25th and the 75th centiles and
the middle line to the median. Levels of CSF C18 ceramide were
significantly higher (p = 0.002) among participants with a CSF AD
profile compared to those without.
were negatively associated with C18 ceramide when
adjusted for age, gender, and education (st.  = –0.36,
p = 0.007). T-tau (st.  = 0.41, p = 0.005) and S100B
(st.  = 0.51, p = 0.001) positively associated with
C18 ceramide when adjusted for the same covariates.
Statistically significant, albeit weaker, associations
were detected between the same measures when lin-
ear regression was not adjusted for demographic
variables. Levels of other CSF proteins (NFL, YKL-
40, GFAP) and test scores presenting verbal episodic
memory (RAVLT, Story) did not significantly asso-
ciate with levels of C18 ceramide. One subject did
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Table 3
Linear regression estimates (unadjusted and adjusted) for the asso-
ciation between various measures and levels of CSF C18 ceramide
CSF C18 ceramide (A.U.)a
Unadjusted Adjusted
model model∗
St.  p St.  p
Demographics
Age, y –0.02 0.902 –0.05 0.765
Education, y –0.05 0.688 –0.07 0.596
CSF proteinsa
A42 (pg/ml) –0.35 0.006 –0.36 0.007
T-tau (pg/ml) 0.30 0.018 0.41 0.005
P-tau (pg/ml) 0.17 0.188 0.21 0.129
T-tau/A42 0.44 < 0.001 0.52 < 0.001
NFL (ng/ml) 0.03 0.835 0.05 0.782
YKL-40 (ng/ml) 0.11 0.411 0.25 0.194
S100B (pg/ml) 0.37 0.004 0.51 0.001




–0.02 0.893 –0.01 0.928
RAVLT delayed recall,
scoreb
–0.18 0.339 –0.29 0.095
Story immediate recall,
score
–0.13 0.356 –0.14 0.345
Story delayed recall,
score
–0.13 0.305 –0.15 0.335
A.U., arbitrary units; RAVLT, Rey Auditory Verbal Learning Test.
Numbers present standardized beta coefficients (st.). ∗Adjusted
for age, gender, and years of education. aValues log2-transformed
and autoscaled before analysis. bAnalysis based on 59 subjects,
with one missing.
not take the RAVLT test, and therefore the analyses
involving RAVLT immediate and delayed recall were
only based on 59 subjects. This did not skew compar-
isons between RAVLT and other regression estimates,
as results in Table 3 did not change when calculated
again without that subject.
The statistically significant relationships between
the levels of proteins and C18 ceramide (p < 0.05)
from Table 3 are depicted in Fig. 4. The associations
were estimated with Pearson’s coefficients, which
are equal to the unadjusted standardized beta coef-
ficients (st. ) in Table 3. Pearson’s coefficients were
also calculated for the CSF markers within each CSF
profile group (Table 4), but none reached statistical
significance (p > 0.05).
DISCUSSION
We used an untargeted lipidomic approach to iden-
tify CSF lipid species associated with a signature
CSF profile reflecting AD pathology. A total of
1008 m/z features were detected, with eight selected
as candidate markers. Out of these, one was fully
confirmed as corresponding to the lipid species C18
ceramide. Our results showed that C18 ceramide lev-
els were higher among subjects with a CSF AD
profile. Relationships were also detected between
established AD markers (A42, T-tau) and C18
ceramide. Higher levels of C18 ceramide associated
with lower levels of A42 and higher levels of T-
tau. In addition, levels of the inflammatory marker
S100B positively related to C18 ceramide. Overall,
our results indicate that CSF C18 ceramide levels
could increase during pathological changes in the
early stages of AD.
Ceramides, the core constituents of sphingolipid
metabolism, are composed of a sphingosine back-
bone linked to a fatty acid chain of varying carbon
atom length (C14-C26) [59]. Alterations in sphin-
golipid metabolism have been observed in healthy
aging and in neurodegenerative diseases, including
AD [60]. They play essential roles in the structural
stability of membranes and as signaling molecules
affect differentiation, proliferation, inflammation,
and apoptosis [61, 62]. Ceramides are synthesized via
two main pathways in eukaryotic cells [63]. In the sal-
vage pathway, sphingomyelin is hydrolyzed through
sphingomyelinase (SMase) to produce ceramide,
which can be further metabolized to sphingosine by
ceramidase. Ceramides can also be generated through
the de novo pathway via anabolism of serine and
palmitate. Results from cellular and animal studies
suggest that both direct and indirect mechanisms by
which ceramides can contribute to an increase in A
levels and AD pathogenesis [64]. Ceramides stimu-
late A generation by stabilizing -secretase enzyme
BACE1 and increasing its half-life [65, 66]. Further-
more, soluble and fibrillar forms of A can induce
degradation of SM to ceramide by SMases [67, 68]
through oxidative stress-mediated mechanisms [69].
This positive loop of ceramide production possi-
bly contributes to immune activation and neuronal
loss in AD. Long-chain ceramides, specifically C18
ceramide, have also been linked to tau phosphoryla-
tion through modulation of PP2A activity [70–74].
Several postmortem studies have found increased
levels of ceramide in brain tissues of AD patients
compared to healthy controls [60, 69, 75–77]. Two
of the studies [60, 76] examined different ceramide
species, with long-chain ceramide levels (C18 and
C24) being significantly elevated in the AD group.
Han et al. [75] observed the highest elevation of total
ceramide in the brains of patients with mild AD,
compared to those with severe AD and to controls,
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Fig. 4. Pearson’s correlations between CSF levels of a) A42, b) T-tau, c) T-tau/ A42, d) S100B and CSF C18 ceramide. Normalized
peak area arbitrary units (A.U.). All CSF measures were log2-transformed and autoscaled before analysis. C18 ceramide levels significantly
correlated with levels of the core AD markers A42, T-tau, and inflammatory marker S100B.
Table 4
Pearson‘s correlations between selected CSF markers and levels
of CSF C18 ceramide within CSF profiles
CSF C18 ceramide (A.U.)a
CSF non-AD CSF AD
profile n = 26 profile n = 34
r p r p
CSF proteinsa
A42 (pg/ml) –0.04 0.86 –0.25 0.15
T-tau (pg/ml) 0.23 0.25 –0.20 0.25
P-tau (pg/ml) –0.20 0.34 –0.13 0.47
T-tau/A42 0.32 0.11 0.08 0.67
NFL (ng/ml) –0.09 0.68 –0.07 0.70
YKL-40 (ng/ml) 0.08 0.70 0.02 0.90
S100B (pg/ml) 0.39 0.052 0.21 0.24
GFAP (ng/ml) 0.16 0.43 0.17 0.34
A.U., arbitrary units. aValues log2-transformed and autoscaled
before analysis.
indicating early changes in the pathological pro-
cesses of AD. To further confirm the implications
of ceramide metabolism in AD, upregulation [78]
and increase in activity of enzymes [77] controlling
ceramide synthesis have been observed in brain areas
(temporal and frontal cortices) affected in the early
stages of the disease.
While postmortem studies are essential, in vivo
studies are the only way to ascertain the role of lipids
in early AD pathogenesis and whether these lipids
may be indicators or predictors of disease progres-
sion. The most informative medium for studying lipid
changes in the brain is the CSF, since it is in direct
contact with the brain interstitial fluid. Very few CSF
studies have been published comparing ceramide lev-
els in AD patients to other groups. Fonteh et al. [79]
found slightly higher, albeit not significant, levels
of ceramide in AD compared to MCI and control
groups in supernatant fluid of CSF. In another study
[80], patients with AD had significantly higher levels
compared to controls with other neurological condi-
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tions. A study by Mielke et al. [81], examined the
relationship between different ceramide species in
relation to A and tau levels in CSF. A positive cor-
relation was found between C18 ceramide and all
A species except A42 as well as tau levels in a
cohort of cognitively healthy individuals aged 36–69
years (n = 91) with a parental history of AD. In con-
trast with cellular studies, no significant correlation
was found between the lipid species and P-tau. The
same study also found a negative association between
the longer carbon chain species (C20, C22, and C26)
and performance on cognitive tests reflecting verbal
episodic memory (delayed recall) or working mem-
ory. Our results expand upon the findings from this
study. The results we present show a significant pos-
itive relationship between levels of C18 ceramide
and T-tau, but not with P-tau, among the cohort of
patients at risk of or at the early stages of dementia.
Association between C18 ceramide and verbal epi-
sodic memory (immediate or delayed recall) was also
not detected. No significant relationship was found
with NFL levels, which is interesting considering it
is a marker for neurodegeneration and white mat-
ter changes, and SM, a precursor of ceramide, is
enriched in the myelin sheath of neurons. A possi-
ble explanation is CSF C18 ceramide being a marker
of apoptosis, rather than degradation of myelinated
axons. Evidence supports the role of ceramides in
neuronal apoptosis, initiating a cascade of biochemi-
cal alterations leading ultimately to neuronal death
[64]. In contrast with the study by Mielke et al.
[81], we showed higher levels of C18 ceramide
associating with lower levels of A42, one of the
primary toxic species of amyloid [82]. A possible
reason could be that all subjects in our study were
already at the symptomatic pre- or early stages of
dementia, and it is not unlikely that the relation-
ship between the analytes strengthens during the
progression of AD. Our study also found a pos-
itive association between levels of C18 ceramide
and inflammatory marker S100B, but not YKL-40
and GFAP. Our hypothesis is that the relationship
could be due to higher concentrations of ceramides
and S100B, as both have been associated with the
induction of neuronal apoptosis [26, 64]. In high
doses, extracellular S100B has been shown to cause
neuronal death by activation of the receptor for
advanced glycation end products (RAGE). The pro-
tein can, by excessive stimulation of RAGE expressed
in neurons, hyperactivate the Ras/MEK/ERK path-
way, which consequently leads to apoptosis [83,
84]. S100B can also, indirectly, lead to neu-
ronal death through the release of nitric oxide by
astrocytes and microglia via RAGE-dependent acti-
vation [85, 86].
There are several limitations to our study. First,
our sample size was relatively small, with a vast
number of features compared to the number of sub-
jects, resulting in little power and a considerable risk
of type-II errors. Corrections for multiple compar-
isons were, therefore, not performed when comparing
levels of features between groups in the discovery
set. A more significant validation set would also
have allowed for evaluation of accuracy in distin-
guishing between CSF profile groups using multiple
lipid species simultaneously as predictors. Second,
our study did not include a healthy control group
or patients with moderate to severe AD. It also
included very few participants with other dementias.
It would be of interest to examine the relationships
between ceramides and AD-related markers in CSF in
a more diverse cohort, for a better evaluation of C18
ceramide as a marker of AD progression and severity,
preferably in a longitudinal study. Third, information
about the APOE genotype of subjects was not avail-
able, and therefore, its potential effect on results could
not be adjusted for [87].
In summary, our results indicate that CSF C18
ceramide levels associate with established markers
of AD pathology (A42 and T-tau) and inflammation
(S100B) at the symptomatic pre- and early stages
of dementia. These findings suggest that ceramide
metabolism could influence the pathophysiological
processes during the early stages of AD. Furthermore,
ceramides could potentially serve as therapeutic tar-
gets, with strategies aiming at reducing ceramide
levels to slow down the progression of the disease.
Longitudinal studies are, however, needed to validate
the pathological implications of these results.
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